Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05054959 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence

Study acronym: ICONA
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Dec 31, 2022 to Dec 31, 2023 Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 31, 2027 to Dec 31, 2028 · Interventions: consolidation chemotherapy (Other), induction chemotherapy (Other) to Consolidation CAPOX Chemotherapy (Drug), Induction CAPOX Chemotherapy (Drug) · 4 morev2 Show 7 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 31, 2027 to Dec 31, 2028
    • Interventions: consolidation chemotherapy (Other), induction chemotherapy (Other) to Consolidation CAPOX Chemotherapy (Drug), Induction CAPOX Chemotherapy (Drug)
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description expanded, about 31 words
    • Site details revised
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to identify the most promising treatment sequence in total neoadjuvant therapy for locally advanced rectal cancer with a high risk of recurrence.
Trial Details
NCT Number NCT05054959
Lead Sponsor Institute of Oncology Ljubljana
Conditions Locally Advanced Rectal Cancer
Enrollment 62 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov